Department Primary Care and Population Health, University College London, Royal Free Campus, London, NW32PF, UK.
Epidemiology and Public Health Group, Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, St Luke's Campus, Exeter, EX1 2LU, Devon, UK.
Curr Diab Rep. 2023 Nov;23(11):307-314. doi: 10.1007/s11892-023-01522-2. Epub 2023 Aug 11.
Sarcopenic obesity (SO) is a growing public health problem in older adults. Whether SO confers higher risk of cardiometabolic disease and mortality than obesity or sarcopenia alone is still a matter of debate. We focus on recent findings on SO and cardiometabolic health and mortality in older adults.
SO is associated with increased mortality compared to non-sarcopenic obesity, but similar mortality risk compared to sarcopenia without obesity. SO is associated with a higher risk of cardiovascular disease (CVD), diabetes, and physical disability than obesity or sarcopenia alone. SO, in the presence of diabetes, is associated with the highest risk of CVD and chronic kidney disease. A definition and diagnostic criteria for SO has recently been proposed (ESPEN and EASO). SO is associated with more adverse outcomes overall than sarcopenia or obesity alone. Future research is required to assess the impact of the new SO definition on health outcomes.
骨骼肌减少性肥胖(SO)是老年人日益严重的公共健康问题。SO 是否比肥胖或单纯性肌少症具有更高的心血管代谢疾病和死亡率风险仍存在争议。我们重点关注最近关于 SO 与老年人的心血管代谢健康和死亡率的研究结果。
与非肌少性肥胖相比,SO 与更高的死亡率相关,但与无肥胖的肌少症相比,SO 具有相似的死亡率风险。SO 与心血管疾病(CVD)、糖尿病和身体残疾的风险高于肥胖或单纯性肌少症。在存在糖尿病的情况下,SO 与 CVD 和慢性肾脏病的风险最高相关。最近提出了 SO 的定义和诊断标准(ESPEN 和 EASO)。SO 与单纯性肌少症或肥胖相比,总体上与更多不良结局相关。需要进一步的研究来评估新的 SO 定义对健康结果的影响。